Dong-A ST Co., Ltd. (KRX:170900)
South Korea · Delayed Price · Currency is KRW 38,250
+750 (2.00%)
At close: Aug 28, 2026
Dong-A ST Revenue
Dong-A ST had revenue of 224.66B KRW in the quarter ending June 30, 2026, with 15.81% growth. This brings the company's revenue in the last twelve months to 860.94B, up 15.38% year-over-year. In the year 2025, Dong-A ST had annual revenue of 808.78B with 15.89% growth.
Revenue (ttm)
860.94B
Revenue Growth
+15.38%
P/S Ratio
0.42
Revenue / Employee
512.77M
Employees
1,679
Market Cap
361.45B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 808.78B | 110.91B | 15.89% |
| Dec 31, 2024 | 697.87B | 33.89B | 5.10% |
| Dec 31, 2023 | 663.98B | 28.59B | 4.50% |
| Dec 31, 2022 | 635.39B | 42.16B | 7.11% |
| Dec 31, 2021 | 593.23B | 6.50B | 1.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Dong-A Socio Holdings | 1.52T |
| JW Holdings | 1.01T |
| Suheung | 765.90B |
| Huons | 616.80B |
| Ildong Pharmaceutical | 582.33B |
| Samjin Pharmaceuticals | 274.03B |
| Shinpoong Pharmaceutical Co.,Ltd | 239.07B |
| Bukwang Pharmaceutical | 200.68B |
Dong-A ST News
- 1 year ago - Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA - Financial Post
- 2 years ago - US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA® - Financial Post
- 2 years ago - US FDA Approves Dong-A ST's IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA® - Benzinga